As its high-dose Eylea continues to duke it out with Roche’s Vabysmo to be the go-to treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME), Regeneron is hitching its ...
May 2 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc (REGN.O), opens new tab missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug ...
April 25 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the ...
Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results